Abstract All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy.
Introduction
Hypertension is a common disorder in adults around the globe and is among the most common attributable causes of mortality [1] . The goal of antihypertensive therapy is to maintain blood pressure (BP) of \140/90 mmHg for most people [2] [3] [4] [5] [6] [7] . Recent hypertension guidelines recommend that diuretics, calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are all appropriate initial antihypertensive therapies for most people. In the USA, it is suggested that African-Americans with hypertension should be started on diuretics or CCBs because of evidence-based clinical efficacy results. In addition, ACE inhibitors or ARBs are advocated for people with stage I-II hypertension and type 1 or 2 diabetes [3] .
ARBs have been in clinical use since 1995 and are known to be effective antihypertensive agents with excellent tolerability profiles. ARBs have additive BP-lowering effects when they are combined with thiazide diuretics and dihydropyridine CCBs, without increasing adverse event rates. Furthermore, ARBs have proven mortality and morbidity effects in heart failure and chronic renal disease, particularly when associated with type 2 diabetes. Concerns were raised surrounding the association of ARBs with development of solid cancers and coronary artery disease. These issues have largely been dismissed by both clinicians and US Food and Drug Administration (FDA) regulators [8] [9] [10] . Herein, we review the pharmacology and pharmacokinetics of ARBs. We also present pertinent research trials comparing the antihypertensive effects and cardiovascular benefits of ARBs, including the safety and tolerability issues encountered.
Pharmacology of Angiotensin Receptor Blockers
The renin-angiotensin-aldosterone system has been a major target pathway for development of antihypertensive medications. The four classes of medications that are involved in this pathway include ACE inhibitors, angiotensin II receptor blockers (ARBs), aldosterone antagonists and direct renin inhibitors. The interest in this pathway is due to the action of angiotensin II on the vascular system, renal sodium and water handling, and cellular proliferation [11] . Inhibition of ACE only partially inhibits formation of angiotensin II. Angiotensin II activates two types of angiotensin II receptors (ATR): ATR 1 and ATR 2 . ATR 1 are abundant in the vessels, brain, heart, kidney, adrenal gland and nerves, while ATR 2 are prominently expressed in the fetus but decrease in number during the postnatal period, where they are only available in small numbers in the adult kidney, adrenal gland, heart, brain, uterus and ovary [12] . Activation of ATR 1 increases inositol triphosphate and various arachidonic acid metabolites, and decreases cyclic adenosine monophosphate. This causes generalized vasoconstriction from contraction of vascular smooth muscle, increases in aldosterone, resulting in increased sodium reabsorption in the proximal tubule, and cell growth in the arteries and heart [11] . Angiotensin II also facilitates catecholamine release from the adrenal medulla and nerve endings, inducing sympathetic nervous system hyperactivity [13] . Thus, antagonizing ATR 1 causes a reduction in both cardiac afterload and preload [11] . The antihypertensive property of ARBs is mainly due to a reduction of peripheral vascular resistance [14] . Angiotensin II is believed to have an important mechanistic role in promoting cardiovascular diseases that is unrelated to its effect on BP. Several animal studies have shown that it causes cardiac hypertrophy even in the absence of elevated BP [15] . Alderman et al. [16] found that individuals with a high renin-sodium profile have a greater risk of myocardial infarction than those with a normal or low profile. ATR 2 function remains unclear, but its stimulation may inhibit cell growth, cell differentiation and apoptosis, and may cause vasodilation [17] . Animal studies show that ATR 2 stimulation improves cardiac function and prevents cardiac remodelling post-myocardial infarction [18] .
The eight ARBs approved for use in the USA and Europe are nonpeptide compounds characterized by having biphenyl, tetrazole, benzimidazole or nonbiphenyl nontetrazole groups (Table 1) . Candesartan, olmesartan, irbesartan, losartan and valsartan have a common tetrazolobiphenyl structure; candesartan and telmisartan have a common benzimidazole group; and eprosartan has a nonbiphenyl, nontetrazole chemical structure [19] . With the exception of irbesartan, all active ARBs have a free carboxylic acid group. On the other hand, azilsartan medoxomil is structurally similar to candesartan, except it has 5-oxo-1,2,4-oxadiazole in place of the tetrazole ring.
ARBs have more affinity for ATR 1 than for ATR 2 and can block the activities of angiotensin II on ATR 1 regardless of whether it was created from ACE or other enzymes such as cardiac chymase. ATR 1 binding affinity is not directly correlated with the antihypertensive effect of ARBs. All ARBs are insurmountable antagonists, except for losartan [14, 20] . Higher concentrations of angiotensin II cannot overcome the effect of an insurmountable ARB, but the impact of surmountability of ATR 1 blockade on final health outcomes has not been established [17] . Table 1 lists the pharmacokinetic characteristics of the eight available ARBs, including the half-life, time to maximum plasma concentration (T max ), bioavailability, elimination route, drug interaction and cytochrome P450 (CYP) metabolism [21] [22] [23] [24] [25] [26] [27] [28] [29] . All ARBs increase renal reabsorption of lithium, so concomitant use with lithium should be avoided. Their maximum BP effects occur about 3-6 h after administration [14, 19] .
Pharmacokinetic Considerations
Losartan undergoes first-pass metabolism in the liver via the CYP system to form its active metabolite EXP-3174, which is 10-40 times more potent than losartan when given intravenously [14] . Its dose must be decreased by half in patients with severe hepatic impairment [30] . Although food delays its absorption and reduces its maximum plasma concentration (C max ), this is not clinically significant [14] . Fluconazole, a CYP2C9 inhibitor, increases the half-life of EXP-3174 but reduces its biological creation from losartan to a greater extent, decreasing its area under the curve (AUC) and C max by 47 and 30 %, respectively. Rifampin, a uridine 5 0 -diphosphoglucuronosyltransferase glucuronosyl transferase and pan-CYP enzyme inducer, decreases the AUCs of losartan and EXP-3174 by 35 and 40 %, respectively. As such, any CYP2C9 enzyme inhibitors or inducers may reduce the effectiveness of losartan, and this must be considered during drug selection [30] .
Three ARBs (candesartan cilexetil, olmesartan medoxomil and azilsartan medoxomil) are prodrugs and require activation in the gastrointestinal tract and liver to their active forms (candesartan, olmesartan and azilsartan, respectively) [31] [32] [33] . The C max of olmesartan is increased by 14 % in elderly patients, but this is not clinically significant. The mean AUC of olmesartan is also significantly increased in patients with severe renal impairment (creatinine clearance \20 mL/min) and, while caution is advised, dose adjustment is not recommended [32] .
Eprosartan, irbesartan, telmisartan and valsartan are not prodrugs and do not require metabolic activation. Irbesartan has one of the highest bioavailabilities among the ARBs. Irbesartan also exhibits a nearly linear dose response, with a plateau at 300 mg [14, 17, 34] . Telmisartan is the longest-acting angiotensin II receptor blocker on the market, with a mean half-life of 24 h. It has a rapid onset of action of about 0.5-1.0 h [14, 35] . Telmisartan coadministration with digoxin increases plasma digoxin levels, which may lead to toxicity secondary to P-glycoprotein blockade [36] . The bioavailability of valsartan is higher in its solution formulation than in capsule form [37] .
Efficacy of Angiotensin Receptor Blockers

Blood Pressure Reductions with Angiotensin
Receptor Blocker Monotherapy Table 2 provides a summary of the initial and maximum doses, as well as the dosing intervals, for ARBs [22] [23] [24] [25] [26] [27] [28] [29] . Antihypertensive efficacy is assessed by determining mean BP reductions from baseline, derived from the trough (end of dosing period) clinic BP readings or from ambulatory BP measurements. Table 3 lists randomized controlled trials directly assessing inter-agent antihypertensive effectiveness [21, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . The key findings regarding comparative efficacy in ARB monotherapy trials are highlighted below.
In the CLAIM studies, candesartan cilexetil doses of 16 and 32 mg/day were found to be more potent than losartan doses of 50 and 100 mg/day, respectively [38, 39] . Candesartan 16 mg/day also reduced clinic BP to a greater extent than losartan 100 mg/day [39] . In a trial of olmesartan medoxomil 20 mg/day, ambulatory systolic BP values were lowered more than with valsartan 80 mg/day and losartan 50 mg/day, and similarly to irbesartan 150 mg/day [44] .
Forced titration of telmisartan from 40 mg and 80 mg/ day has been observed to be more efficacious in reducing BP than losartan 50 mg and 100 mg/day [48] . In a small study evaluating telmisartan 80 mg/day, less BP reduction was observed than with valsartan 160 mg/day following 12 weeks of therapy [49] . Much larger controlled trials have found that telmisartan 80 mg/day was superior to valsartan 160 mg/day [55] . Furthermore, during the last 6 h of the once-daily dosing periods, telmisartan 80 mg/day lowered both systolic and diastolic BP to a greater extent than valsartan 160 mg/day [50] . Irbesartan 300 mg/day (but not 150 mg/day) has been found to have superior antihypertensive effects to losartan 100 mg/day [51] . Irbesartan 150 mg/day did demonstrate greater BP reductions than valsartan 80 mg/day [52] . Azilsartan medoxomil 40 mg/day was found to be equivalent to olmesartan 40 mg/day but superior to valsartan 320 mg/day, while the antihypertensive effect of azilsartan 80 mg/day was superior to both valsartan 320 mg/day and olmesartan 40 mg/day, using ambulatory systolic BP as the primary efficacy endpoint [21] . Eprosartan at 600 and 1,200 mg/day significantly reduces BP compared with placebo but has not been studied in comparison with other ARBs [56] .
Blood Pressure Reductions with Combination Therapies
Most hypertension guidelines recommend that combination therapy should be used as initial therapy in stage 2 hypertension or in those patients for whom a single agent does not result in hypertension control. Fixed-dose combination (FDC) pills containing ARBs/diuretics and ARBs/amlodipine are increasingly used in the USA. Diuretic administration leads to activation of the reninangiotensin system, and ARBs blunt this effect, allowing for the maximum benefit from diuretic-induced sodium depletion. This complementary action improves tolerability, since the dose of the components may be lowered [57] . The addition of ARBs also mitigates the negative metabolic effects associated with diuretics, including hypokalaemia, hyperuricaemia and glucose intolerance [58] . Similarly, the combination of ARBs with amlodipine has been shown to be highly effective and well tolerated as FDCs. Dihydropyridine calcium antagonists can cause peripheral oedema secondary to arterial vasodilatationinduced increases in capillary hydrostatic pressure. ARBs normalize capillary hydrostatic pressure by improving venous return to the heart and hence counteract the effect of amlodipine in a large proportion of individuals with oedema. Fogari et al. [59] showed that amlodipine alone causes an increase in ankle-foot volume and pretibial subcutaneous tissue pressure, and the addition of an ARB significantly attenuated these effects. Tables 4 and 5 list randomized controlled trials assessing the efficacy of therapies combining ARBs with diuretics and ARBs with amlodipine versus their component single therapies [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . The key findings regarding comparative efficacy in ARB combination therapy trials are highlighted below.
In the nine trials assessing the impact of adding a thiazide diuretic to an ARB versus the diuretic alone, combination therapy reduced the systolic and diastolic BP values significantly more than diuretic monotherapy (at equivalent doses) after 6-12 weeks [61] [62] [63] [64] [65] [66] [67] [68] 76] . In one trial, the addition of 12.5 mg/day of hydrochlorothiazide to candesartan 16 mg/day resulted in BP reductions similar to those seen with candesartan 32 mg/day [60] .
There are three approved ARB/amlodipine FDCs: olmesartan/amlodipine, telmisartan/amlodipine and valsartan/amlodipine. Trials have shown that the addition of amlodipine to an ARB resulted in greater BP reductions than each component at similar doses. More patients in the combination therapy groups responded to achieve the target BP, compared with the component monotherapies, and with comparable adverse events [71] [72] [73] [74] . Trials performed in South Korea and Japan have also shown beneficial effects of adding amlodipine to losartan and candesartan, but these combinations of losartan/amlodipine and candesartan/amlodipine are not approved in the USA [75, 76] .
Management of hypertension in African-Americans, hypertension in patients with chronic kidney disease and isolated systolic hypertension in older people are often challenging [77] . In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) cohort, about 31.5 % of black men versus 27.2 % of nonblack men, and 27.2 % of black women versus 24.5 % of non-black women are taking three or more antihypertensive medications [78] . These more complicated patient populations have led to the development of FDCs with three classes of antihypertensives, comprising a thiazide diuretic, an ARB and a dihydropyridine calcium antagonist. The randomized controlled trials assessing the efficacy of these 'triple' FDCs versus their monotherapeutic components are shown in Table 6 [79, 80] .
Calhoun et al. [79] published the first large-scale randomized controlled trial involving patients with stage I-II hypertension (entry BP C145/100 mmHg), assessing the efficacy of triple therapy with valsartan, amlodipine and hydrochlorothiazide versus dual therapy with its components. The valsartan/amlodipine/hydrochlorothiazide combination resulted in mean BP changes from baseline of 39.7/24.7 mmHg at maximum doses of each component. The triple therapy was statistically superior to the dual therapies (p \ 0.0001 for triple therapy versus amlodipine/ hydrochlorothiazide, amlodipine/valsartan and valsartan/ hydrochlorothiazide). At 8 weeks of therapy, 70.8 % of patients receiving the triple therapy achieved control, versus 48.3 % for valsartan/hydrochlorothiazide, 54.1 % for amlodipine/valsartan and 44.8 % for amlodipine/hydrochlorothiazide (all p \ 0.0001) ( Table 6 ).
The TRINITY trial involved 2,492 randomized patients and showed that triple therapy with olmesartan/amlodipine/ hydrochlorothiazide at 40/10/25 mg/day resulted in a 37/22 mmHg reduction in mean BP, compared with 27.5/ 15, 30/17 and 30/18 mmHg BP reductions with amlodipine/hydrochlorothiazide 10/25 mg/day, olmesartan/ hydrochlorothiazide 40/25 mg/day and olmesartan/amlodipine 40/10 mg/day dual therapies, respectively (all p \ 0.001). After week 12, 69.9 % of patients in the triple therapy group achieved goals of BP \140/90 (or \130/ 80 mmHg for patients with diabetes or chronic kidney disease), compared with 41.1, 53.4 and 52.9 % of the amlodipine/hydrochlorothiazide, olmesartan/hydrochlorothiazide and olmesartan/amlodipine combination treatment groups, respectively (all p \ 0.001) [80] . This more effective reduction in BP with triple therapy was not affected by race/ethnicity, body weight or presence of type 2 diabetes mellitus [81] [82] [83] .
Use of Multiple Renin-Angiotensin Blockers
A meta-analysis comprising 38 randomized controlled trials showed no mortality benefit associated with dual ARB and ACE inhibitor therapy, and did reveal an increase in nonfatal adverse events, including hyperkalaemia (potassium level C6.0 mmol/L; relative risk [ [84] .
The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) showed that although the telmisartan/ramipril combination reduced progression of proteinuria in patients with vascular disease (hazard ratio [HR] 0.76 [95 % CI 0.60-0.96], p = 0.019 for combination therapy versus ramipril), the incidence of the composite primary renal outcome (dialysis, doubling of creatinine and death; HR 1.09 [95 % CI 1.01-1.18], p = 0.037) was actually increased with the combination therapy versus ramipril alone [85] .
Similarly, in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints trial (ALTITUDE), the direct renin inhibitor aliskiren or placebo was added to background ACE inhibitor or ARB therapy. The trial was terminated prematurely because of a lack of benefit and an increase in hyperkalaemia (potassium level C6.0 mm/L; 11.2 % in the aliskiren arm versus 7.2 % in the placebo arm, p \ 0.001) and reported hypotension (12.1 % in the aliskiren arm versus 8.3 % in the placebo arm, p \ 0.001) [86] .
Angiotensin Receptor Blockers and Cardiovascular
Outcomes in Patients with Hypertension (Table 7) Data from the INTERHEART (Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction) trial showed that hypertension is one of the top risk factors for acute myocardial infarction, with an odds ratio of 2.48 (99 % CI 2.30-2.68). Other risk factors identified in this population study included current smoking, raised apolipoprotein (Apo)-B/ApoA1, history of diabetes and psychosocial factors [87] . In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial, losartan was found to reduce cardiovascular morbidity and death by 13 %, compared with the beta blocker atenolol (p = 0.021), despite similar reductions in BP among hypertensive patients with left ventricular hypertrophy [88] . Losartan also reduced the incidence of fatal and nonfatal stroke by 25 %, compared with atenolol (p = 0.002). In contrast, losartan did not reduce cardiovascular mortality or myocardial infarction, compared with atenolol [88] . In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial [89] , valsartan did not show an advantage over amlodipine in reducing cardiac mortality and morbidity. However, in VALUE, there was an unexpected difference in BP control, particularly during the first year of the study, with the respectively, p \ 0.0001). These differences likely contributed to the finding that cardiac events were significantly higher in the valsartan arm (Table 7 ). In the Study on Cognition and Prognosis in the Elderly (SCOPE) [90] , involving 4,964 participants aged 70-89 years with hypertension, candesartan (versus placebo) did not result in a significant risk reduction in major cardiovascular events, including myocardial infarction and cardiovascular mortality, but nonfatal stroke was reduced by 27.8 % (95 % CI 1.3-47.2, p = 0.04).
The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRAN-SCEND) study [91] evaluated high-risk patients intolerant of ACE inhibitors with a prior history of cardiovascular disease or diabetes mellitus without heart failure, with about 70 % of the participants being hypertensive. Patients were randomized to telmisartan or placebo added to standard-ofcare therapy (excluding renin-angiotensin blocking therapy). After 56 months of follow-up, telmisartan resulted in fewer major cardiovascular events compared with placebo [93] .
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial included patients with type 2 diabetes mellitus with nephropathy. Losartan reduced the incidence of doubling of serum creatinine (risk reduction 25 %, p = 0.006), with a 35 % reduction in proteinuria, and reduced the incidence of end-stage renal disease (risk reduction 28 %, p = 0.002) versus placebo, but without a mortality benefit. Except for lowering the rate of first hospitalizations for heart failure (risk reduction 32 %, p = 0.005), the composite endpoint of morbidity and mortality from cardiovascular causes was similar for losartan therapy and placebo after 3.4 years of therapy [94] . In the Irbesartan Diabetic Nephropathy Trial (IDNT) involving hypertensive patients with diabetic nephropathy, the irbesartan arm had a 37 % lower risk of doubling serum creatinine versus the amlodipine arm (p \ 0.001) and 33 % lower than the placebo group (p = 0.003). The rate of development of end-stage renal disease was nominally lower with irbesartan than with amlodipine and placebo, but it did not reach statistical significance (p = 0.07) [95] .
Angiotensin Receptor Blockers in Post-myocardial Infarction and Heart Failure Patients
Angiotensin blockade is a major therapeutic strategy in patients with heart failure, providing a balanced reduction in preload and afterload when reduced systolic function occurs after an ischaemic event or because of nonischaemic cardiomyopathy. In a number of trials, ARBs have been compared with ACE inhibitors in patients with systolic heart failure. In the Losartan Heart Failure Survival Study (ELITE II), losartan 50 mg/day was not found to be superior to captopril 150 mg/day (given in three doses) in reducing all-cause mortality in patients with New York Heart Association (NYHA) class II-IV heart failure and a left ventricular ejection fraction (LVEF) B40 %. Of note, approximately 80 % of the patients in ELITE II had ischaemic causes of heart failure, and 50 % were classified as NYHA class II (mild-moderate 59 ], p = 0.08). Not surprisingly, fewer patients discontinued treatment prematurely because of adverse effects in the losartan group, compared with captopril (9.7 % versus 14.7 %, p = 0.001) [96] . The Valsartan in Acute Myocardial Infarction (VAL-IANT) Study showed that valsartan was as effective as captopril in reducing all-cause mortality among patients with a history of acute myocardial infarction (valsartan group versus captopril; HR 1.00 [97.5 % CI 0.90-1.11], p = 0.98), but the combination of captopril plus valsartan did not prove to be superior to the monotherapy regimens [97] . The Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) Study demonstrated that another ARB, losartan, was comparable to captopril in reducing overall mortality in patients with a history of myocardial infarction and heart failure with left ventricular dysfunction (LVEF \35 %; RR 1.13 [95 % CI 0.99-1.28], p = 0.07) [98] .
The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) study was actually composed of three trials: CHARM-Alternative (LVEF B40 % and ACE intolerant) versus placebo; CHARM-Added (LVEF B40 % in patients already on Patients were allowed to use ACE inhibitors and beta blockers ACE inhibitors); and CHARM-Preserved (LVEF [40 %) and were also placebo controlled [99] . In the CHARMAlternative study, candesartan was associated with a significant 23 % relative risk reduction in CV death or hospitalization for CHF, with a number needed to treat of about 14 patients [100] . In CHARM-Added, candesartan was associated with a significant 15 % relative risk reduction of CV death or hospital admission with an absolute risk reduction of about 4 % after 41 months of median follow-up. There was a higher permanent discontinuation rate in the candesartan group than in the placebo group (24 versus 18 %, p = 0.0003), because of adverse events, including hyperkalaemia and doubling of serum creatinine. [101] . In the CHARM-Preserved trial, there was no significant reduction in cardiovascular mortality and morbidity in patients with preserved left ventricular function receiving candesartan versus placebo after 36.6 months of follow-up [102] . The Valsartan Heart Failure Trial (Val-HeFT) demonstrated beneficial effects of ARBs in heart failure patients, particularly through those participants unable to tolerate ACE inhibitors. Patients with chronic NYHA class II-IV heart failure were randomized to receive valsartan (a target dose of 160 mg twice daily) or placebo. Fewer patients in the valsartan group reached the combined endpoint of mortality and morbidity defined by cardiac arrest with resuscitation, hospitalization for heart failure or administration of intravenous inotropic or vasodilator drugs (RR 0.87 [97.5 % CI 0.77-0.97], p = 0.009). There were also significant improvements in NYHA class, ejection fraction and quality of life in the valsartan arm, compared with placebo (p \ 0.01). In contrast to the findings of CHARM-Added [101] , the addition of valsartan to an ACE inhibitor adversely affected mortality (p = 0.009) and was associated with a trend towards increases in combined mortality and morbidity (p = 0.10) [103] .
To date, there is no established specific therapy for heart failure associated with preserved ejection fraction, other than maintaining good BP control and managing volume status. As noted above, in the CHARM-Preserved trial, there was no improvement in the primary outcome with candesartan relative to placebo [102] . A second and larger trial, Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) [104] , involved patients at least 60 years of age with NYHA class II-IV heart failure and an LVEF of at least 45 %. Irbesartan 300 mg/day did not reduce mortality or hospitalization for any cardiovascular cause, compared with the control group. The rates of hospitalization due to cardiovascular causes were 70.6 and 74.3 per 1,000 patient-years in the irbesartan and placebo groups, respectively (HR 0.95 [95 % CI 0.85-1.08], p = 0.44).
Safety and Tolerability of ARBs in Hypertension
Safety of Angiotensin Receptor Blocker Monotherapies
ARBs have demonstrated excellent safety profiles alone and in combination with other antihypertensive therapies during the past 20 years. The tolerability profiles of ARBs are similar to that of placebo and superior to those of ACE inhibitors. For example, ACE inhibitors increase the risk of cough two-to threefold over placebo and may cause up to 0.1-0.2 % rates of angioedema, which can be life threatening in a minority of cases [105] . Cough and angioedema most likely result from accumulation of bradykinin and substance P, which are both degraded by ACE, and they recur with reintroduction of the ACE inhibitor or use of another ACE inhibitor [106] . In a meta-analysis involving 11 randomized controlled trials evaluating the tolerability of ARBs versus ACE inhibitors, diuretics and placebo, the cough risk of the ARBs was comparable to that of placebo (RR 1.01 [95 % CI 0.74-1.39]) [107] . Among patients intolerant of ACE inhibitors, angioedema was a rare event among ARB users, with an incidence of 0.12 % versus 0.07 % in the placebo arm (RR [107] . Hence, ARBs have been demonstrated to be one of the better-tolerated antihypertensive class, with improved persistence in the management of hypertension or other comorbidities, and this class is an appropriate option for patients who are intolerant of ACE inhibitors. The most commonly reported adverse events in randomized controlled trials comparing ARBs with placebo include headache, respiratory infection, dizziness and fatigue. In these analyses, the rates of adverse events with ARBs were comparable to those seen with placebo. Reported discontinuation rates in major ARB trials are low. For example, Andersson and Neldam [38] reported that just 1.5 % patients withdrew from their clinical study because of adverse events. In a study comparing losartan and candesartan performed by Bakris et al. [54] , four of the 654 patients (0.6 %) receiving either candesartan or losartan required hospitalization, but none of these events was considered treatment related. Withdrawal from the study was rare and comparable between treatment arms. In a study evaluating the comparative efficacy and safety of olmesartan, valsartan and irbesartan, Oparil et al. [44] reported that seven out of 588 patients (1.2 %) withdrew because of adverse events, including fatigue, malaise and cough. In a similar trial, Giles et al. [45] reported 16.9, 13.5, 10.3 and 17.9 % total discontinuation rates with olmesartan, losartan, valsartan and placebo, respectively. Fewer than 1 % of randomized patients reported serious adverse events, and all of these events were considered unrelated to the study medication.
In 2012, a gastroenterology group at the Mayo Clinic published a case series involving 22 patients, suggesting an association between olmesartan medoxomil and development of sprue-like enteropathy, based on the clinical presentation, histopathology and temporal relationship to the drug [108] . In July 2013, the FDA issued a warning that olmesartan may cause sprue-like enteropathy, but this warning was later removed from the label of the drug [109] . A case-control study published recently [110] showed no statistically significant association between olmesartan and diarrhoea among patients undergoing upper endoscopy (OR 1. In a trial that compared the efficacy and safety of telmisartan, valsartan and placebo, seven out of 207 patients withdrew from the study because of adverse events. Treatment-related adverse event rates were reported as 2.1 % with telmisartan 40 mg, 4.5 % with telmisartan 80 mg, 2.8 % with valsartan 80 mg and 3.5 % with valsartan 160 mg [47] .
Discontinuation rates for irbesartan 300 mg (1.4 %) have been reported to be comparable to those seen with placebo (3.4 %) and the lower dose of irbesartan (150 mg; 2.1 %). Again, like other ARBs described above, the overall reported rates of adverse events, including headache, musculoskeletal pain, dizziness and fatigue, were comparable between irbesartan and placebo [51] . No serious adverse events have been considered due to irbesartan (0.5 %) or valsartan (1.4 %) use [52] .
Safety of Angiotensin Receptor Blockers in Combination with Thiazide Diuretics
A number of large safety and efficacy randomized controlled trials of ARB/thiazide diuretic combination therapies have reported adverse events that were mild to moderate in intensity, transient and generally unrelated to the study drug. The different ARB-diuretic combinations have similar safety and tolerability to each other.
Candesartan with Hydrochlorothiazide
Reported adverse events in trials with ARBs in combination with hydrochlorothiazide diuretics are mild to moderate, transient and/or unrelated to treatment. Evaluation of the safety of candesartan/hydrochlorothiazide 16/12.5 mg/ day has not shown serious adverse events and, other than one case of hypokalaemia with combination therapy, none were considered treatment related [60] . In a 24-week study of lower doses of this combination (candesartan/hydrochlorothiazide 8/6.25 mg/day), there were no significant changes in plasma glucose, haemoglobin A 1c , low-density lipoprotein (LDL), high-density lipoprotein (HDL), creatinine, potassium and uric acid. No serious adverse events and discontinuations due to adverse events were reported [111] . Higher doses of FDC with candesartan/hydrochlorothiazide 32/12.5 or 32/25 mg/day have also been found to be safe and well tolerated. In a large pooled analysis of safety, Mengden et al. [112] reported 49 out of 4,098 patients (1.2 %) having adverse events, seven of which were considered serious (0.2 %).
Eprosartan with Hydrochlorothiazide
The ARB eprosartan was studied by Sachse et al. [61] , who reported 65 out of 157 patients (41.4 %) having an adverse event, of which 19 were probably treatment related in the eprosartan monotherapy group (600 mg/day), compared with 69 out of 152 patients (45.4 %), of which 25 were probably treatment related in the eprosartan/hydrochlorothiazide combination group (600/12.5 mg/day).
Olmesartan with Hydrochlorothiazide
In a trial involving olmesartan/hydrochlorothiazide combinations of 40/25, 20/25, 40/12.5 and 20/12.5 mg/day, no differences in adverse events by treatment group thought to be related to drug were reported. About 0.19 % of patients had serious adverse events, and none were reported to be due to the study drug [62] . Fogari et al. [113] reported that 3.9 % of patients in an olmesartan/hydrochlorothiazide 40/12.5 mg/day group had drug-related adverse events, compared with 0.7 % in the olmesartan 40 mg/day monotherapy treatment arm. About 2.3 % and 1.4 % of patients in the combination and monotherapy groups, respectively, discontinued their participation in the study because of adverse events.
Losartan with Hydrochlorothiazide
The percentages of adverse events, both laboratory and clinical, in the trials of losartan/hydrochlorothiazide combination therapy at different doses were comparable to those seen with placebo, except for the incidence of dizziness, which was more common in the combination therapy group [63] . The combination therapy group receiving losartan/hydrochlorothiazide 100/25 mg/day had fewer total clinical adverse events than those receiving losartan monotherapy 150 mg/day (43.3 versus 52.6 %), including a rise in creatinine (0.5 versus 1.1 %). The reported serious adverse event rates were also greater with monotherapy compared with combination therapy (3.6 versus 1.0 %), but these findings were not statistically significant [64] .
Irbesartan with Hydrochlorothiazide
The INCLUSIVE trial [65] had a 3 % rate of serious adverse events, with three occurring in the placebo arm, four in the hydrochlorothiazide monotherapy 12.5 mg/day arm, eight in the irbesartan/hydrochlorothiazide 150/12.5 mg/day arm and seven in the irbesartan/hydrochlorothiazide 200/25 mg/day arm. All were judged as unrelated to the medication, except for one event of hypotension in the irbesartan/hydrochlorothiazide 150/12.5 mg/day arm, which was probably drug related [65] . Lapuerta and Franklin [114] actually reported more adverse events with irbesartan monotherapy than with irbesartan/hydrochlorothiazide combination therapy 300/25 mg/day (36.1 versus 29.9 %). However, hyperkalaemia and hypokalaemia were slightly more common with the combination therapy (0.2 and 0.6 %, respectively) than with monotherapy (0 and 0.4 %, respectively). Hypotension and dizziness were rare in both treatment arms. Severe hypokalaemia (\3 mmol/L) was not observed [114] .
Valsartan with Hydrochlorothiazide
With forced titration, dizziness was more frequent with the combination of valsartan/hydrochlorothiazide therapy than with monotherapy (160/320 ? 12.5/25 mg) [66] . Otherwise, the safety profile of valsartan/hydrochlorothiazide combination therapy was comparable to that of valsartan monotherapy. Discontinuation rates were greatest with valsartan monotherapy 320 mg/day (7.1 % compared with 3.0 % in the valsartan/hydrochlorothiazide combination group and 2.4 % in the placebo group). During the 54-week extension of the study, treatment-related adverse events were identified in 14.9 % of patients receiving valsartan/ hydrochlorothiazide 320/25 mg/day and in 10.5 % of patients receiving valsartan/hydrochlorothiazide 320/12.5 mg/day [115] . In a meta-analysis done by Weir et al., there was an increasing frequency of reported dizziness at increasing component doses of valsartan/hydrochlorothiazide therapy [116] . Finally, hyperuricaemia was reported less often with valsartan/hydrochlorothiazide than with hydrochlorothiazide alone (5.0 versus 8.6 %) [117] .
Telmisartan with Hydrochlorothiazide
Lacourcière and Martin [67] reported that telmisartan/ hydrochlorothiazide combination therapy had a similar discontinuation rate to telmisartan monotherapy. The incidence of adverse events between these two therapies was also comparable. Although more patients in the combination treatment group complained of dizziness, this finding did not reach statistical significance. Neldam and Edwards [69] reported comparable drug-related adverse event rates with telmisartan/hydrochlorothiazide 80/25 and 80/12.5 mg/day (5.7 versus 5.0 %), resulting in discontinuation rates of 1.7 and 3.0 %, respectively. Two of the serious adverse events were reported as drug related, including atrial flutter in a patient receiving 80/25 mg/day of the combination medication and third-degree atrioventricular block in another patient receiving 80/12.5 mg/day of the combination medication. Hypokalaemia was rare.
Azilsartan with Chlorthalidone
In a pivotal study of this newer ARB with the diuretic chlorthalidone, Sica et al. [70] reported higher rates of increases in creatinine and dizziness with higher doses of the azilsartan/chlorthalidone combination than with chlorthalidone alone. Hypotension was rare, but there were three reported episodes of syncope in the combination treatment group. The reported rises in creatinine were transient, and the values returned to baseline after drug discontinuation.
Safety of Angiotensin Receptor Blockers in Combination with Amlodipine
A number of large safety and efficacy randomized controlled trials of ARB/amlodipine combination therapies have reported adverse events that were low in frequency, mild to moderate in intensity, transient and typically unrelated to the study drug. The different ARB-amlodipine combinations have similar safety and tolerability to each other.
Olmesartan with Amlodipine
Chrysant et al. [71] reported comparable treatment-related adverse events with the combination of olmesartan/amlodipine and with placebo (19.6-33.1 versus 29.6 %). The frequency of peripheral oedema was lower in patients treated with olmesartan/amlodipine in combination than with amlodipine monotherapy, reaching statistical significance with olmesartan/amlodipine 20/10 mg/day and 40/10 mg/day, compared with amlodipine 10 mg/day (p = 0.032 and p = 0.011, respectively). Two cases of drug-related hypotension were reported with olmesartan/ amlodipine that resulted in discontinuation from the study. No differences in serum chemistry, haematology or urinalysis parameters between treatment groups were observed.
Valsartan with Amlodipine
Flack et al. [73] found that the rates of peripheral oedema with the valsartan/amlodipine combination (12.6 %) were not different from those seen with amlodipine monotherapy (9.5 %; p = NS). In a larger, better powered trial by Philipp et al. [72] , there was a significantly higher frequency of peripheral oedema with amlodipine monotherapy than with combination therapy.
Telmisartan with Amlodipine
In a double-blind, randomized trial by Neutel et al. [74] , drug-related adverse events were reported in 12.6 % of patients receiving telmisartan/amlodipine 80/10 mg/day, 6.9 % receiving telmisartan 80 mg/day and 16.4 % receiving amlodipine 10 mg/day. The reported serious adverse events were small in number (0.7 versus 0.9 and 0.9 %). The frequency of peripheral oedema was greater with amlodipine monotherapy than with combination therapy (13.2 versus 9.3 %).
Safety of Angiotensin Receptor Blockers in Combination with Diuretics and Amlodipine (Triple Therapy)
There are two combination therapies with three antihypertensive agents that include an ARB (valsartan and olmesartan), a thiazide diuretic and amlodipine (known as triple therapies). The most common reported adverse events with valsartan/amlodipine/hydrochlorothiazide 320/10/25 mg/day were dizziness, headache and peripheral oedema. Dizziness occurred more commonly with triple therapy and valsartan/hydrochlorothiazide (320/25 mg/ day) than with the component monotherapies, the valsartan/amlodipine (320/10 mg/day) combination and the amlodipine/hydrochlorothiazide (10/25 mg/day) combination. Peripheral oedema occurred less frequently with triple therapy (4.5 %) and valsartan/hydrochlorothiazide (0.9 %) than with amlodipine/hydrochlorothiazide (8.9 %) or amlodipine/valsartan (8.5 %) [72] . Olmesartan/amlodipine/hydrochlorothiazide is another triple combination medication approved for the treatment of hypertension. Oparil et al. [80] reported similar rates of dizziness with olmesartan/amlodipine/hydrochlorothiazide 40/10/25 mg/day and olmesartan/hydrochlorothiazide 40/25 mg/day but higher rates than with olmesartan/ amlodipine and amlodipine/hydrochlorothiazide at maximum doses (9.9, 10.0, 4.9 and 3.1 %, respectively). Again, peripheral oedema was more frequent in patients receiving the amlodipine-containing regimen than in the other groups. The rates of drug-related adverse events were comparable between triple therapy and dual therapy.
Twenty-three out of 574 patients (4.0 %) in the triple therapy group withdrew from the study because of drug-related adverse events. Hypotension occurred more frequently with triple therapy than with olmesartan/ hydrochlorothiazide 40/25 mg/day, amlodipine/hydrochlorothiazide 10/25 mg/day and olmesartan/amlodipine 40/10 mg/day (2.1, 0.7, 0.2 and 0 %, respectively). Dizziness and vertigo occurred in 11.3, 10.7, 3.4 and 5.5 % of patients in each study group, respectively. Syncope was rare (\1 %) but was reported more with triple therapy.
Safety of Angiotensin Receptor Blockers in Outcome Studies or Analyses
Angiotensin Receptor Blockers and Myocardial Infarction
After the VALUE trial showed a statistically significant increased incidence of myocardial infarction in the valsartan arm, questions were raised regarding the safety of ARBs. This unexpected relationship of ARBs with MI was termed the 'ARB-MI paradox'. Strauss and Hall [118] published a review article regarding this controversy and suggested that ARBs may be inferior to ACE inhibitors in preventing coronary heart disease. It was hypothesized that this could be a result of activation of ATR 2 due to ATR 1 blockade resulting in cardiac fibrosis and hypertrophy. Other plausible mechanisms included higher levels of plasminogen activator inhibitor-1 and lower levels of bradykinin with ARB use than with ACE inhibitor use. The results of two multicentre randomized controlled trials-Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) and Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy (ORIENT)-showed increased cardiac death rates with olmesartan use [119, 120] . The ROADMAP trial, involving 4,447 diabetic patients without overt nephropathy but with one additional cardiovascular risk factor, reported 15 cardiovascular deaths out of 2,232 patients in the olmesartan arm, compared with three deaths out of 2,215 patients in the placebo arm [119] . The ORI-ENT trial reported ten cardiovascular deaths out of 282 patients in the olmesartan group and three deaths out of 284 patients in the placebo arm [120] . The FDA initially released a statement indicating that the benefit of olmesartan use outweighs the risk but, after an extensive safety review, they found no association between olmesartan and increased cardiovascular risk [121] .
A meta-analysis by Cheung et al. [122] , which included three major trials (LIFE, SCOPE and VALUE) with 29,375 patients in total, showed that ARBs are associated with an increased risk of myocardial infarction (RR 1.12 [95 % CI 1.01-1.26], p = 0.041). On the other hand, another three studies showed a neutral effect [123] [124] [125] . However, in the most comprehensive and well-performed meta-analysis, by Bangalore et al. [126] , which involved 37 trials with 147,020 patients in total, no evidence of an increased risk of myocardial infarction (an absolute increase of 0.3 %, corresponding to a number needed to harm of C333) was determined. In fact, conclusive evidence of a relative risk reduction of stroke, heart failure and new-onset diabetes with ARBs, compared with controls, was the key finding in this large analysis.
Hence, there is no evidence that ARB use increases the risk of myocardial infarction. Clearly, the benefits of ARBs have been demonstrated over the past 25 years in numerous clinical outcome trials.
Angiotensin Receptor Blockers and Cancer
In 2010, substantial controversy regarding administration of ARBs causing certain solid cancers occurred following a meta-analysis of nine trials, totally approximately 34,000 patients, by Sipahi et al. [8] . This analysis showed an increased risk of new cancers in the ARB group In a much more comprehensive and well-performed meta-analysis on this topic, Bangalore et al. [9] . There were also no differences in cancerrelated mortality among the four antihypertensive therapy classes compared with placebo [9] .
There have been two observational studies [10, 127] that supported the conclusions of the larger meta-analysis performed by Bangalore et al. [9] . Pasternak et al. [10] performed a large cohort study (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) [10] . Another large cohort study involving 377,649 new ARB users at least 18 years of age, from the UK General Practice Research Database, assessed the association between ARBs and cancer risk [127] . After a mean follow-up of 4.6 years, ARB use was not found to increase the overall risk of cancer (adjusted HR 1.03 [95 % CI 0.99-1.06], p = 0.10) versus ACE inhibitors. On the other hand, there was an increased risk of breast and prostate cancer, which translated to 0.5-1.1 extra cases, respectively, per 1,000 person-years of follow-up in those with the highest baseline cancer risk. Longer duration of ARB use was also not associated with a higher overall cancer risk [127] .
Conclusions
ARBs have proven to be a highly effective class of agents for treatment of hypertension and its comorbidities over the past two decades. There are eight ARBs approved for use in the USA for treatment of hypertension ( Table 2) . As the ARBs were developed during the 1990s, they were accompanied by longer half-lives and, in some cases, greater potency, which translated into enhanced BP reductions and/or durations of action. Therapies combining ARBs with diuretics, calcium antagonists and, most recently, the beta blocker nebivolol [128] have shown better BP reduction in clinical trials than the monotherapy components. While there are theoretical benefits of combining ARBs with ACE inhibitors (e.g. proteinuria reduction), event-driven trials have not shown a benefit and in fact have demonstrated increases in adverse renal events. Hence, there is no clinical rationale for combining ARBs with ACE inhibitors (or direct renin inhibitors) in the management of hypertension. The excellent safety and tolerability profile of the ARB class has improved the adherence to antihypertensive therapy and enhanced our ability to manage hypertension in those patients with sensitivities to other antihypertensive drug classes, including ACE inhibitors. 
